https://unsplash.com/photos/tV-RX0beDp8

New Collaboration to Evaluate Nirogacestat in Combination with ABBV-383 in Relapsed or Refractory Multiple Myeloma

• Post author:Jessica Lynn
• Post published:December 14, 2021
• Post category:Multiple Myeloma

In a recent news release, biopharmaceutical companies AbbVie, Inc. and SpringWorks Therapeutics, Inc. ("SpringWorks") shared that the two had entered into a joint clinical trial collaboration agreement. Through this collaboration,…

Continue Reading New Collaboration to Evaluate Nirogacestat in Combination with ABBV-383 in Relapsed or Refractory Multiple Myeloma

Source: https://unsplash.com/photos/6F2mPewg2RA

First Subject Dosed in Laquinimod Trial for Uveitis

• Post author:Jessica Lynn
• Post published:December 14, 2021
• Post category:Uveitis

On December 10, 2021, biotechnology company Active Biotech shared that the first subject was dosed within a Phase 1 clinical trial evaluating laquinimod for non-infectious non-anterior uveitis. What is particularly…

Continue Reading First Subject Dosed in Laquinimod Trial for Uveitis

source: pixabay.com

First Volunteers Dosed in ALG-055009 Trial for NASH

• Post author:Jessica Lynn
• Post published:December 14, 2021
• Post category:Nonalcoholic steatohepatitis

In a recent news release, biopharmaceutical company Aligos Therapeutics, Inc. ("Aligos") shared that the first healthy volunteers were dosed in a Phase 1 clinical trial evaluating ALG-055009 for nonalcoholic steatohepatitis.…

Continue Reading First Volunteers Dosed in ALG-055009 Trial for NASH

source: pixabay.com

Lomecel-B for HLHS Earns Orphan Drug Status

• Post author:Jessica Lynn
• Post published:December 14, 2021
• Post category:hypoplastic left heart syndrome

On December 6, 2021, biotechnology company Longeveron Inc. ("Longeveron") announced that its investigational therapeutic candidate Lomecel-B earned Orphan Drug designation from the FDA. The therapy is designed to treat patients…

Continue Reading Lomecel-B for HLHS Earns Orphan Drug Status

source: pixabay.com

Luspatercept-aamt Earns Priority Review for Beta Thalassemia

• Post author:Jessica Lynn
• Post published:December 14, 2021
• Post category:Beta Thalassemia

According to Pharmacy Times, the FDA recently granted Priority Review status to luspatercept-aamt (Reblozyl). The therapy, for which its developer has submitted a supplemental biologics license application (sBLA), is designed…

Continue Reading Luspatercept-aamt Earns Priority Review for Beta Thalassemia

Thor_Deichmann / Pixabay

Doctors Repurpose DFMO for Bachmann-Bupp Syndrome

• Post author:Jessica Lynn
• Post published:December 14, 2021
• Post category:Rare Disease

In 2016, Marley Berthold was born. But doctors, and her parents, noticed some concerning signs. Marley's silver hair had fallen out in clumps; she had macrocephaly (an abnormally large head)…

Continue Reading Doctors Repurpose DFMO for Bachmann-Bupp Syndrome

AllStripes corporate lifestyle photo shoot at Salesforce park and AllStripes offices in San Francisco, Calif., Tuesday, Aug. 17, 2021. Photo by Alison Yin/Alison Yin Photography (Provided to PW by AllStripes)

AllStripes: How this HealthTech Company Leverages Science to Advance Rare Disease Research (Pt. 2)

• Post author:Jessica Lynn
• Post published:December 14, 2021
• Post category:Rare Disease

Nancy Yu co-founded AllStripes with a vision in mind: to unlock more treatment options for those with rare diseases. In Part 1 of our interview, Patient Worthy sat down with…

Continue Reading AllStripes: How this HealthTech Company Leverages Science to Advance Rare Disease Research (Pt. 2)